Thyrocare TechnologiesNSE:THYROCARE -1.94%88 Gross Margin % is 74.69% as of Mar. 2026, which is 4% above its 10-year median of 72.12. GuruFocus rates NSE:THYROCARE with a GF Score™ of 88/100 and a GF Value™ of ₹394.39 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 78.46% on this metric.
NSE:THYROCARE's Gross Margin % is ranked better than 78.46% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs NSE:THYROCARE: 73.52
Thyrocare Technologies had a gross margin of 74.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Thyrocare Technologies was 1.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Thyrocare Technologies had a gross margin of 74.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thyrocare Technologies Gross Margin % Related Terms
Thyrocare Technologies Gross Margin % Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Thyrocare Technologies (NSE:THYROCARE) has a Gross Margin % of 74.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Thyrocare Technologies and its competitors. This is near median its historical median of 72.12. Over the past decade, Thyrocare Technologies' Gross Margin % has ranged from 66.49 to 73.52. According to the industry distribution chart, Thyrocare Technologies ranks #42 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 21.5%.
Is Thyrocare Technologies' Gross Margin % too high?
Thyrocare Technologies' current Gross Margin % of 74.69% is near median its 10-year median of 72.12. Over the past 10 years, this metric has ranged from a low of 66.49 to a high of 73.52. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Thyrocare Technologies' value of 74.69% is 46.5% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #42 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #42 out of 195 companies for Gross Margin %. This places Thyrocare Technologies in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.97. Thyrocare Technologies' value of 74.69% is 46.5% above this benchmark. Historically, Thyrocare Technologies' own Gross Margin % has ranged from 66.49 to 73.52 over the past decade. While the company's 10-year median is 72.12 vs. the industry median of 50.97, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Gross Margin % of 74.69% is 46.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Gross Margin % is 74.69%, which is near median its own 10-year median of 72.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹394.39, compared to a current price of ₹521.70 — trading 32.3% above its estimated fair value. The current Gross Margin % is 74.69%, which is near median its 10-year median of 72.12 and 46.5% above the Medical Diagnostics & Research industry median of 50.97. Thyrocare Technologies' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Gross Margin % is 74.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹521.70 is trading 32.3% above its estimated GF Value™ of ₹394.39.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Gross Margin %: 74.69% (near median its 10-year median of 72.12)
GF Value™: ₹394.39 vs. price of ₹521.70 (32.3% above fair value)
Industry Position: 46.5% above the Medical Diagnostics & Research median (#42 of 195)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
88GF Score
Get the complete analysis for NSE:THYROCARE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
